Fidelity Disruptive Communications ETF (NASDAQ: FDCF)

最新ニュース Fidelity Disruptive Communications ETF (NASDAQ:FDCF)

Technology

Communication Services

Other

Consumer Cyclical

Real Estate

Energy

Industrials

The fund investing at least 80 percent of assets in securities of disruptive communications companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services.

Sea Ltd.

NVIDIA Corporation

Meta Platforms, Inc.

Arista Networks, Inc

Alphabet Inc Class A

Snap Inc Class A

Amazon.Com Inc

American Tower Corp

Taiwan Semiconductor Manufacturing Co. Ltd. - Adr

PDD Holdings Inc ADR

Fidelity Disruptive Communications ETF

Analyst Color

Social Media

Analyst Ratings

Tech

BMBL

FDCF

FMET

RVER

WCEO

Bumble Inc.（NASDAQ:BMBL）（バンジンガによると）は先週、企業収益の大幅な不振を受けて、出会い系アプリの競争の激しい世界での成長が望めないことが明らかになったと、1人のアナリストが語った。

バンジンガ　出会い系アプリ業界の競争激しい

FORUM ENERGY METALS CORP by Forum Energy Metals Corp.

Forum Energy Metals Corp

Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) reported its third-quarter results after Tuesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/g41919462/occidental-announces-third-quarter-2024-results">figures from the quarter. </a>
The Details:&nbsp;Occidental Petroleum reported quarterly adjusted earnings of $1.00 per share, beating the analyst consensus estimate of 74 cents. Quarterly revenue came in at $7.15 billion, missing the consensus estimate of $7.23 billion. 
<ul>
<li>Strong operational performance drove operating cash flow of $3.8 billion and operating cash flow before working capital of $3.1 billion.</li>
<li>Capital spending of $1.7 billion and contributions from noncontrolling interest of $47 million resulted in quarterly free cash flow before working capital of $1.5 billion.</li>
<li>Total company production of 1,412 Mboed exceeded the mid-point of guidance by 22 Mboed.</li>
<li>Midstream and marketing exceeded the mid-point of guidance for pre-tax adjusted income by $145 million.</li>
<li>OxyChem exceeded guidance with pre-tax income of $304 million.</li>
<li>Repaid $4 billion of debt, achieving nearly 90% of Occidental&#8217;s short-term debt reduction target.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/earnings/24/11/41914981/bitcoin-miners-hive-digital-hut-8-bitfarms-to-report-earnings-as-future-of-crypto-has-never-been-brighter">Bitcoin Miners Hive Digital, Hut 8, Bitfarms To Report Earnings As Future Of Crypto &#8216;Has Never Been Brighter&#8217;</a>
&#8220;Strong operational performance across all segments has resulted in our highest quarterly operating cash flow this year,&#8221; said president and CEO Vicki Hollub. 
&#8220;The integration of CrownRock is off to a great start in terms of personnel and operations, and we have made significant progress in our deleveraging efforts, achieving nearly 90% of our short-term debt reduction target,&#8221; Hollub added. 
The company will host a conference call to discuss the results at 1 p.m. ET Wednesday.&nbsp;
OXY Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Occidental Petroleum shares are up 0.52% after-hours at $50.55 at the time of publication Tuesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Earnings

News

Commodities

After-Hours Center

Movers

Occidental Petroleum Shares Steady After Mixed Q3 Results

Oriental Culture Holding H1 EPS $(0.28) Up From $(0.50) YoY, Sales $0.447M Down From $0.799M YoY

Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.14 by 42.86 percent. The company reported quarterly sales of $131.577 million which missed the analyst consensus estimate of $138.440 million by 4.96 percent. This is a 16.49 percent increase over sales of $112.955 million the same period last year.

Earnings Misses

ARMN

Aris Mining Q3 2024 Adj. EPS $0.08 Misses $0.14 Estimate, Sales $131.577M Miss $138.440M Estimate

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. The company reported quarterly sales of $1.141 million which missed the analyst consensus estimate of $1.263 million by 9.64 percent. This is a 54.87 percent decrease over sales of $2.528 million the same period last year.

BOLT

Bolt Biotherapeutics Q3 2024 GAAP EPS $(0.40) Misses $(0.35) Estimate, Sales $1.141M Miss $1.263M Estimate

Earnings Beats

TERN

Terns Pharma Q3 EPS $(0.28) Beats $(0.34) Estimate

Guidance

GRDN

Guardian Pharmacy Services Sees FY24 Revenue $1.205B-$1.215B Vs $1.191B Estimate;  Sees Adj. EBITDA $86.5M-$87M

Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) reported quarterly losses of $(2.00) per share which missed the analyst consensus estimate of $0.21 by 1052.38 percent. The company reported quarterly sales of $314.39 million which beat the analyst consensus estimate of $303.16 million by 3.71 percent. This is a 19.66 percent increase over sales of $262.74 million the same period last year.

Guardian Pharmacy Service Q3 2024 GAAP EPS $(2.00) Misses $0.21 Estimate, Sales $314.39M Beat $303.16M Estimate

Adams Resources &amp; Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AE#AMEX">AE</a>) reported quarterly losses of $(1.76) per share which missed the analyst consensus estimate of $(0.28) by 528.57 percent. The company reported quarterly sales of $695.163 million which beat the analyst consensus estimate of $654.996 million by 6.13 percent. This is a 8.61 percent decrease over sales of $760.614 million the same period last year.

Adams Resources & Energy Q3 2024 GAAP EPS $(1.76) Misses $(0.28) Estimate, Sales $695.163M Beat $654.996M Estimate

TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) reported its third-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g41918828/terawulf-reports-third-quarter-2024-financial-results">details from the report.&nbsp;&nbsp;</a>
The Details:&nbsp;TeraWulf reported quarterly GAAP losses of six cents per share, which missed the analyst consensus estimate for losses of three cents. Quarterly revenue came in at $27.05 million, which missed the analyst consensus estimate of $34.27 million and is an increase over sales of $18.95 million from the same period last year.
<ul>
<li>TeraWulf self-mined 555 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) across the Lake Mariner and Nautilus Cryptomine facilities, which represented a 43.4% decrease relative to the same quarter last year.</li>
<li>Total value of Bitcoin self-mined was $33.9 million compared to $27.6 million in the prior year&#8217;s quarter.</li>
<li>Power cost per Bitcoin self-mined increased year-over-year, to $30,448 per Bitcoin, up from $9,322 per Bitcoin in the third-quarter of 2023 due to an approximate doubling in network difficulty and the Bitcoin reward halving in April 2024.</li>
<li>Total self-mining hashrate capacity of 10.0 EH/s as of Sept. 30, 2024, represents an increase of 100% relative to the same prior year period.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/earnings/24/11/41914981/bitcoin-miners-hive-digital-hut-8-bitfarms-to-report-earnings-as-future-of-crypto-has-never-been-brighter">Bitcoin Miners Hive Digital, Hut 8, Bitfarms To Report Earnings As Future Of Crypto &#8216;Has Never Been Brighter&#8217;</a>
&#8220;The third quarter and the beginning of the fourth quarter marked a pivotal turning point for TeraWulf, as we delivered strong results across our strategic, financial, and operational objectives,&#8221; said Paul Prager, chairman and CEO of TeraWulf.
&#8220;The sale of our interest in the Nautilus joint venture not only generated a substantial return but also sharpened our focus on scaling high-performance computing at Lake Mariner. Securing an expanded ground lease with exclusive rights to 750 MW of infrastructure capacity is a significant milestone in our growth strategy. Combined with the success of our $500 million capital raise, we are exceptionally well-positioned to seize new opportunities in both Bitcoin mining and HPC hosting as we enter 2025,&#8221; Prager added. 
WULF Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, TeraWulf shares are down 3.51% after-hours at $8.23 at the time of publication Tuesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Pete Linforth from Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

WULF

TeraWulf Stock Tumbles After Worse-Than-Expected Q3 Results

SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year. The company reported $7.92 million in sales this quarter. This is a 7.39 percent decrease over sales of $8.55 million the same period last year.

SunLink Health Systems Q1 EPS $(0.06), Same YoY, Sales $7.92M Down From $8.55M YoY

Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(1.15) by 23.48 percent. This is a 98.14 percent increase over losses of $(47.37) per share from the same period last year.

CRGX

Cargo Therapeutics Q3 EPS $(0.88) Beats $(1.15) Estimate

WIIM

Ginkgo Bioworks shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its FY24 revenue guidance.

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.43) by 69.77 percent. This is a 133.33 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $233.60 thousand which missed the analyst consensus estimate of $350.00 thousand by 33.26 percent. This is a 660.91 percent increase over sales of $30.70 thousand the same period last year.

BRTX

BioRestorative Therapies Q3 EPS $(0.13) Beats $(0.43) Estimate, Sales $233.60K Miss $350.00K Estimate

Serina Therapeutics Q3 EPS $0.13 Down From $0.23 YoY, Sales $14K Down From $29K YoY

Psychemedics Q3 EPS $(0.09) Up From $(0.36) YoY, Sales $5.20M Down From $5.70M YoY

TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) reported quarterly losses of $(0.05) per share. This is a 61.54 percent increase over losses of $(0.13) per share from the same period last year. The company reported $547.00 thousand in sales this quarter. This is a 1.13K percent increase over sales of $(53.00 thousand) the same period last year.

TXMD

TherapeuticsMD Q3 EPS $(0.05) Up From $(0.13) YoY, Sales $547.00K Up From $(53.00K) YoY

A Washington-based researcher has filed a lawsuit against the Drug Enforcement Administration (DEA), alleging multiple legal violations in the agency's process of <a href="https://www.benzinga.com/topic/cannabis-rescheduling">rescheduling marijuana</a>. As Forbes <a href="https://www.forbes.com/sites/dariosabaghi/2024/11/12/researcher-sues-dea-over-marijuana-rescheduling-process/">reported</a>, the complaint, filed in the U.S. District Court for Western Washington, names the Department of Justice, Attorney General Merrick Garland, DEA Administrator Anne Milgram and DEA Judge John J. Mulrooney II as defendants.
<h3 class="wp-block-heading">Accusations Of Flawed Process</h3>
David Heldreth, CEO of psychedelic research firm Panacea Plant Sciences, claims the DEA's recent actions violate federal law and constitutional principles. He seeks injunctive and declaratory relief to halt the agency&#8217;s rulemaking process until these issues are addressed. The case marks a significant challenge to the DEA's handling of marijuana rescheduling, an effort initiated in 2022 following President <a href="https://www.benzinga.com/markets/cannabis/24/05/38880719/biden-announces-monumental-marijuana-rescheduling-doj-to-take-next-steps">Joe Biden's directive to reexamine marijuana&#8217;s classification</a>.
Currently, marijuana is listed as a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I</a> drug, a category reserved for substances with no accepted medical use and a high potential for abuse. Reclassification to Schedule III would acknowledge its medical potential and lower abuse risk, placing it alongside substances like <a href="https://www.benzinga.com/topic/ketamine">ketamine</a> and anabolic steroids. Such a shift would also exempt cannabis businesses from <a href="https://www.benzinga.com/topic/280e">Section 280E</a> of the Internal Revenue Code, which prevents them from being able to deduct operating expenses, a significant financial burden on the industry.
<h3 class="wp-block-heading">A Shift In Federal Marijuana Policy</h3>
In April 2024, the DEA endorsed a recommendation from the Department of Health and Human Services (HHS) to reschedule marijuana from Schedule I to Schedule III. This decision was seen as a step forward for the <a href="https://www.benzinga.com/cannabis">cannabis industry</a>, potentially easing regulatory restrictions and facilitating greater access to traditional banking services. Following this recommendation, the DEA initiated a <a href="https://www.benzinga.com/markets/cannabis/24/07/39932698/deas-call-for-public-input-on-cannabis-garnered-42-000-comments-majority-want-total-legalization">62-day public comment period</a>, which concluded on July 22, gathering roughly 43,000 comments from a wide range of stakeholders, including medical professionals, law enforcement and industry advocates.
Despite submitting a request to participate in the hearings, Heldreth's company, Panacea Plant Sciences, was excluded from the list of 25 participants chosen by Milgram. This exclusion is at the heart of Heldreth's lawsuit, which accuses the DEA of bias and of sidelining critical voices in favor of larger, established players in the industry.
<h3 class="wp-block-heading">Allegations Of Constitutional Violations And Tribal Neglect</h3>
Heldreth's complaint highlights several alleged legal violations in the DEA's rulemaking process. He contends that the agency failed to consult Native American tribes despite the significant impact that rescheduling marijuana would have on tribal law enforcement and health services. The lack of federal funding to support these changes, Heldreth argues, places an undue burden on tribal governments.
The lawsuit also claims that the DEA's process favors large cannabis companies with existing Schedule III licenses, effectively shutting out smaller businesses like Panacea Plant Sciences. Heldreth asserts that this exclusion undermines fair participation in the rulemaking process and disproportionately benefits well-established firms.
Additionally, Heldreth challenges the constitutionality of the DEA's Administrative Law Judges (ALJs), arguing that their appointment by the DEA administrator violates Article II of the U.S. Constitution. He calls for a suspension of the ALJ hearings until these issues are resolved, citing bias and a lack of due process in the agency's participant selection.
<h3 class="wp-block-heading">New Political Climate</h3>
The lawsuit emerges during a transitional period in federal marijuana policy. The November election outcome signals potential changes in the cannabis landscape. President-elect Donald Trump has <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">voiced support for reclassifying marijuana at the federal level</a> and expanding banking access for regulated cannabis companies. He also endorsed state-led efforts to legalize recreational marijuana, including a high-profile measure in Florida that ultimately <a href="http://v">failed to pass</a>.
<h3 class="wp-block-heading">What's Next For The DEA's Rulemaking?</h3>
The DEA's rulemaking process continues, with the presiding administrative law judge set to file a report on the gathered testimony. The agency is required to review this report, along with all materials from the public comment period, before issuing its final decision. The DEA must address significant issues raised during the hearings and provide detailed explanations for its conclusions. The final rulemaking, once completed, will be published in the Federal Register, formally enacting any changes to marijuana's scheduling status.
<h3 class="wp-block-heading">Potential Turning Point</h3>
Heldreth's lawsuit could significantly impact small businesses and Native American tribes, challenging the cannabis industry rules. As the debate over marijuana's legal status continues, the case highlights tensions between federal regulators and stakeholders pushing for a more inclusive, transparent drug policy reform.
Cover image made with AI

Cannabis

Government

Psychedelics

Legal

DEA Faces Lawsuit Alleging Bias In Marijuana Rescheduling Process

ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.47) by 4.26 percent. This is a 11.36 percent decrease over losses of $(0.44) per share from the same period last year.

ORIC

ORIC Pharmaceuticals Q3 EPS $(0.49) Misses $(0.47) Estimate

Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. The company reported quarterly sales of $48.280 million which missed the analyst consensus estimate of $50.850 million by 5.05 percent. This is a 21.81 percent decrease over sales of $61.750 million the same period last year.

GROV

Grove Collaborative Hldgs Q3 2024 GAAP EPS $(0.04) Beats $(0.13) Estimate, Sales $48.280M Miss $50.850M Estimate

AZTR

Azitra Q3 Revenue $0 Down From $310.70K YoY

Comments

Fidelity Disruptive Communications ETF

ニュース

最新ニュース Fidelity Disruptive Communications ETF (NASDAQ:FDCF)

ニュース

パートナーシップ

ベンジンガ・グローバル